OvaScience (NASDAQ: OVAS) and Wave Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.
This is a summary of recent ratings and recommmendations for OvaScience and Wave Life Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wave Life Sciences||0||0||6||0||3.00|
This table compares OvaScience and Wave Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wave Life Sciences||-3,338.68%||-59.52%||-48.48%|
Earnings & Valuation
This table compares OvaScience and Wave Life Sciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Wave Life Sciences||$1.49 million||880.07||-$55.40 million||($3.54)||-13.28|
Wave Life Sciences has higher revenue and earnings than OvaScience. Wave Life Sciences is trading at a lower price-to-earnings ratio than OvaScience, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
43.8% of OvaScience shares are owned by institutional investors. Comparatively, 79.7% of Wave Life Sciences shares are owned by institutional investors. 9.5% of OvaScience shares are owned by insiders. Comparatively, 53.0% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Wave Life Sciences beats OvaScience on 10 of the 13 factors compared between the two stocks.
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington’s disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.